The initially identified potential senolytic drugs have been discovered using a hypothesis-driven approach 553 , based on the observation that senescent cells resist apoptosis. The basic drug discovery hypotheses suggested that: (i) senescent cells resist apoptotic stimuli, and (ii) senescent cells are in certain aspects similar to cancer cells that do not divide. Further senolytic drug identification was bioinformatics-based 594 and initially included the natural flavonoid quercetin (CAS # 117-39-5) targeting senescent umbilical vein endothelial cells (HUVECs) and the tyrosine kinase inhibitor dasatinib (CAS # 302962-49-8) targeting senescent primary adipocyte progenitor cells. Other members of this first generation senolytics class included fisetin, luteolin, curcumin, navitoclax, and others. Figure illustrates the use of ChemScape tool within SciFinder n 566 to search for compounds of similar chemical structure to quercetin as potential anti-aging drugs. The efficacy of the suggested senolytic drugs have been demonstrated in model organisms for age-and cellular senescence-associated physical disabilities, insulin resistance, cognitive decline, osteoporosis, osteoarthritis, and cancers. Senolytic agents have the potential to delay, prevent, or treat senescence-and age-related disorders, based on successful forthcoming human clinical trials. Other promising senolytic drugs include acarbose, 17-α-estradiol, and nordihydroguaiaretic acid (NGDA). 588 Recently, new structurally diverse compounds with promising senolytic activity have been identified using deep learning neural networks simulations.